Stroke prevention in atrial fibrillation

被引：23

作者：

Hart R.G. ^{[1
]}

机构：

[1] Department of Medicine (Neurology), University of Texas Health Science Center, San Antonio, TX 78284-7883

来源：

Current Cardiology Reports | 2000年 / 2卷 / 1期

关键词：

Aspirin; Atrial Fibrillation; Warfarin; Ischemic Stroke; Stroke Prevention;

D O I：

10.1007/s11886-000-0025-2

中图分类号：

学科分类号：

摘要：

Nonvalvular atrial fibrillation (AF) is an independent risk factor for stroke. The overall risk of ischemic stroke in patients experiencing AF without prior stroke averages about 5% per year, but varies depending on the presence of coexistent thromboembolic risk factors. Patients with AF with low (about 1% per year), moderate (2%-4% per year) and high ( 6% per year) stroke risks have been identified, but the generalizability of available risk stratification schemes to clinical practice has not been defined. Adjusted-dose warfarin (target International Normalized Ratio [INR] 2-3) is highly efficacious for prevention of stroke in patients with AF (about 60% reduction) and is relatively safe for selected patients, if carefully monitored. Aspirin has a modest effect on reducing stroke (about 20% reduction). The role of transesophageal echocardiography is routine management of AF remains unsettled. Warfarin therapy should be considered for patients with AF predicted to have a high risk of stroke and who can safely receive it. Aspirin may be indicated for patients with AF at low risk for stroke and for those who cannot safely receive adjusted-dose warfarin. For those with moderate stroke risk, individual bleeding risks during anticoagulation and patient preferences should guide antithrombotic therapy. Copyright © 2000 by Current Science Inc.

引用

页码：51 / 55

页数：4

共 25 条

[1]

Wolf P.A., Abbott R.D., Kannel W.B., Atrial fibrillation: A major contributor to stroke in the elderly, Arch Intern Med, 1, pp. 1561-1564, (1987)

[2]

Wolf P.A., Abbot R.D., Kannel W.B., Atrial fibrillation as an independent risk factor for stroke: The Framingham Study, Stroke, 22, pp. 983-988, (1991)

[3]

Hart R.G., Pearce L.A., Miller V.T., Et al., Cardioembolic vs. noncardioembolic stroke in atrial fibrillation: Frequency and effect of antithrombotic agents, Cerebrovascular Dis, (1999)

[4]

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized clinical trials, Arch Intern Med, 154, pp. 1949-1957, (1994)

[5]

The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from three randomized trials, Arch Int Med, 157, pp. 1237-1240, (1997)

[6]

Hart R.G., Benavente O., McBride R., Pearce L.A., Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis, Ann Intern Med, 131, pp. 492-501, (1999)

[7]

Kopeck S.L., Gersh B.J., McGoon M.D., Et al., The natural history of lone atrial fibrillation: A population-based study over three decades N Engl J Med 1987, 317:669 674

[8]

Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1, 066 patients from three clinical trials, Arch Int Med, 158, pp. 1316-1320, (1998)

[9]

Clinical features in patients at risk, Ann Int Med, 116, pp. 1-5, (1992)

[10]

Predictors of thromboembolism in atrial fibrillation II: Echocardiographic features in patients at risk, Ann Int Med, 1, pp. 6-12, (1991)

← 1 2 3 →